Pacific Biosciences Of California (PACB) Enterprise Value Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Enterprise Value Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.57% |
| Dec 31, 2025 | -2,088.43% |
| Sep 30, 2025 | 38.28% |
| Jun 30, 2025 | 23.71% |
| Mar 31, 2025 | 38.94% |
| Dec 31, 2024 | 3.64% |
| Sep 30, 2024 | -2.73% |
| Jun 30, 2024 | -13,551.22% |
| Mar 31, 2024 | 35.77% |
| Dec 31, 2023 | 99.33% |
| Sep 30, 2023 | 53.87% |
| Jun 30, 2023 | 99.03% |
| Mar 31, 2023 | -62.11% |
| Dec 31, 2022 | -7,955.28% |
| Jun 30, 2022 | -8,531.81% |
| Mar 31, 2022 | -132.36% |
| Dec 31, 2021 | -8.12% |
| Jun 30, 2021 | 95.51% |
| Mar 31, 2021 | -198.80% |
| Dec 31, 2020 | -12.43% |